The Role of Sodium-Glucose Cotransporter-2 Inhibitors in the Treatment Paradigm of CKD in Africa: An African Association of Nephrology Panel Position Paper.

From 2015 to 2019, despite an increasing trend for SGLT2i use for T2DM treatment (3.8% to 11.9%), their overall use was relatively lower among patients with atherosclerotic CVD, HF with reduced ejection fraction, and CKD.

also in 63,971 other papers